Amgen Sep 13, 2022 ESMO Data Deepens Understanding of KRAS Inhibitor Activity in Lung, Colorectal Cancer Premium Aug 31, 2022 Amgen's Lumakras Bests Chemo, Meets Primary Endpoint in CodeBreak 200 Trial Aug 9, 2022 Amgen Finetuning Combination Strategy for Lumakras in NSCLC Following Safety Readouts Premium Aug 5, 2022 Amgen Reports Growing Lumakras Sales in Q2 Despite KRAS G12C Testing Challenges Premium Jun 23, 2022 Drugmakers Going After RAS, MAPK Pathway to Tackle Cancers With Variety of KRAS Mutations Premium Jun 7, 2022 Mirati Hoping to Set Apart Adagrasib in Competitive KRAS-Mutant NSCLC Market With CNS Activity Data Premium Jun 6, 2022 Vectibix Outperforms Avastin in First-Line RAS-Wildtype Left-Sided Colorectal Cancer Premium May 12, 2022 Bristol Myers Squibb Scoops Up Rights to BridgeBio's SHP2 Inhibitor May 6, 2022 Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials Apr 28, 2022 Amgen Q1 Revenues Increase 6 Percent With Strong Growth in Lumakras Sales Apr 15, 2022 Novartis Enters KRAS G12C Space With Positive Phase I/II Data in Lung, Colorectal Cancer Apr 11, 2022 One-Third of KRAS-Mutant NSCLC Patients in Amgen's Lumakras Trial Alive After Two Years Premium Feb 18, 2022 Amgen Expanding Enrollment in Lumakras Trial After Promising Data in KRAS-Mutant Pancreatic Cancer Premium Jan 21, 2022 In Brief This Week: AstraZeneca, Daiichi Sankyo, Orgenesis, Amgen Jan 13, 2022 BridgeBio, Amgen to Study SHP2 Inhibitor, Lumakras Combo in KRAS-Mutant Tumors Jan 12, 2022 JP Morgan Healthcare Conference Day 2: Ideaya, Amgen, Revolution Medicines, Monte Rosa, and More Jan 10, 2022 Amgen's Lumykras Garners European Commission Conditional Approval for KRAS-Mutated Lung Cancer Jan 4, 2022 MSK, Amgen Explore Lumakras Combination Regimens to Overcome KRAS Inhibitor Resistance Premium Dec 15, 2021 Amgen Turning to Combination Strategies After Limited Lumakras Efficacy in KRAS-Mutated Colon Cancer Nov 12, 2021 CHMP Recommends Amgen's Lumykras for KRAS G12C-Mutated NSCLC Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
